Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Threonine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL1537459 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL1675354 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL18729492 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL442279 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL2765875 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL8005616 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL1514090 | 1.00 | SLC7A5 (0.50) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL8429463 | 0.96 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL5073181 | 0.96 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2USP2 | |
| Threonine SCHEMBL5073185 | 0.96 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | claimed |
| EP-2477962-A1 | PRODRUGS OF GUANFACINE | Shire LLC (US) | 2012-07-25 | — | — | EP | claimed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | claimed |
| CN-102498094-A | Prodrugs of guanfacine | SHIRE LLC | 2012-06-13 | — | — | CN | claimed |
| WO-2011033296-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-24 | — | — | WO | claimed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | claimed |
| WO-2009043114-A1 | ARSENOXIDE COMPOUND AND METHOD OF USE | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2009-04-09 | — | — | WO | claimed |
| CN-1774259-A | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus | TEVA PHARMA (IL) | 2006-05-17 | — | — | CN | claimed |
| WO-2005051976-A2 | PROTEIN AND PEPTIDE LIGATION PROCESSES AND ONE-STEP PURIFICATION PROCESSES | ANSATA THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | claimed |
| US-5252725-A | α-1-antichymotrypsin, analogues and methods of production | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-10-12 | — | — | US | claimed |
| JP-60027371-A | — | — | None | — | — | JP | disclosed |
| EP-3500671-B1 | METHOD OF SELECTING TARGET SEQUENCES FOR THE DESIGN OF GUIDE RNAS | BROAD INST INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3500670-B1 | METHOD FOR SELECTING TARGET SEQUENCES FOR GUIDE RNA OF CRISPR SYSTEMS | BROAD INST INC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024141784-A2 | BROADLY PROTECTIVE BETACORONAVIRUS VACCINES AND COMPOSITIONS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | disclosed |
| EP-0332225-A2 | Antibody to polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4863857-A | Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0214232-A1 | POLYPEPTIDES COMPLEMENTARY TO PEPTIDES OR PROTEINS HAVING AN AMINO ACID SEQUENCE OR NUCLEOTIDE CODING SEQUENCE AT LEAST PARTIALLY KNOWN AND METHODS OF DESIGN THEREFOR. | UNIV TEXAS (US) | 1987-03-18 | — | — | EP | disclosed |
| WO-1986005208-A1 | POLYPEPTIDES COMPLEMENTARY TO PEPTIDES OR PROTEINS HAVING AN AMINO ACID SEQUENCE OR NUCLEOTIDE CODING SEQUENCE AT LEAST PARTIALLY KNOWN AND METHODS OF DESIGN THEREFOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1986-09-12 | — | — | WO | disclosed |
| JP-S6027371-A | FOOD PRESERVATIVE | SANRAKU INC | 1985-02-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | SLC7A5 121/4885GLRA1 653/4885SLC6A9 237/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | SLC7A5 121/4885GLRA1 653/4885SLC6A9 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.